AMGN Amgen Inc
P/E
24.68
Forward P/E
15.97
Price/Sales
5.15
Beta
0.416
Div Yield
0.0273%
Market Cap
--
Company Analysis
Latest News
Amgen Upgraded to Buy, Boosted by Obesity and Eye-Disease Drug Trials
Wall Street Zen upgraded Amgen Inc. (NASDAQ:AMGN) from hold to buy on June 14, 2026. The stock maintains a consensus hold rating with an average price target...
Amgen's first quarter 2026 revenue grew 6% as strong performance from key growth products offset biosimilar pressures.
Amgen reported first quarter 2026 revenues of $8.6 billion, a 6% year-over-year increase, and non-GAAP EPS of $5.15, up 5% from the prior year. The results...
Amgen Inc Q1 2026 Earnings Preview: What Analysts Expect on April 30, 2026
Amgen is expected to report Q1 2026 revenue of $8.67 billion and adjusted EPS of $4.75, with its current $344.55 share price trading roughly 3.4% below the...
OpenAI Launches GPT-Rosalind with Moderna and Amgen, Targeting Faster Drug Discovery
OpenAI launched GPT-Rosalind, a new series of AI models engineered to accelerate life sciences research. The tool assists scientists in synthesizing evidence,...